Fernand Labrie

Publications

Page 6 of 25, showing 50 records out of 1234 total, starting on record 251, ending on 300

Publication Category Year
984. Labrie, F., Candas, B., Dupont, A., Cusan, L., Gomez, J.L., Suburu, R.E., Diamond, P., Lévesque, J., Bélanger, A. (1999) Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate, 38: 83-91. All publications 1999
983. Labrie, F., Cusan, J., Gomez, J., Levesque, J., Candas, B. (1999) Screening and treatment of localized prostate cancer decreases mortality: first analysis of the first prospective and randomized study on prostate cancer screening. Society of the Study of the Aging Male, 2: 33-43. All publications 1999
982. Labrie, F., Cusan, L., Gomez, J.-L., Bélanger, A., Candas, B. (1999) Long-term combined androgen blockade alone for localized prostate cancer. Mol. Urol., 3: 217-226. All publications 1999
981. Labrie, F., Simard, J., Coquet, A., Leblanc, G., Candas, B. (1999) Relative potency of bicalutamide (Casodex) and Flutamide (Eulexin) [Letter to the Editor: Reply by the authors re: 50: 913-919, 1997]. Urology, 54: 195-197. All publications 1999
980. van der Kwast, T.H., Labrie, F., Têtu, B. (1999) Persistence of high-grade prostatic intra-epithelial neoplasia under combined androgen blockade therapy. Hum. Pathol., 30: 1503-1507. All publications 1999
979. van der Kwast, T.H., Labrie, F., Têtu, B. (1999) Prostatic intraepithelial neoplasia and endocrine manipulation. Eur. Urol., 35: 508-510. All publications 1999
978. van der Kwast, T.H., Têtu, B., Candas, B., Gomez, J.-L., Cusan, L., Labrie, F. (1999) Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapy. Urology, 53: 523-529. All publications 1999
977. Couillard, S., Gutman, M., Labrie, F., Candas, B., Labrie, C. (1999) Effect of the combined treatment with the pure antiestrogen EM-800 and radiotherapy on the growth of human ZR-75-1 breast cancer xenografts in nude mice. Cancer Res., 59: 4857-4863. All publications 1999
976. Gutman, M., Couillard, S., Labrie, F., Candas, B., Labrie, C. (1999) Effects of the antiestrogen EM-800 (SCH 57050) and cyclophosphamide alone and in combination on growth of human ZR-75-1 breast cancer xenografts in nude mice. Cancer Res., 59: 5176-5180. All publications 1999
975. Hida, N., Poulin, R., Veilleux, R., Labrie, F. (1999) Differential androgen sensitivity is associated with clonal heterogeneity in steroid metabolism, ornithine decarboxylase regulation and IL-1alpha action in mouse mammary tumor cells. J. Steroid Biochem. Mol. Biol., 71: 71-81. All publications 1999
974. Labrie, F., Labrie, C., Bélanger, A., Simard, J., Gauthier, S., Luu-The, V., Mérand, Y., Giguère, V., Candas, B., Luo, S., Martel, C., Singh, S.M., Fournier, M., Coquet, A., Richard, V., Charbonneau, R., Charpenet, G., Tremblay, A., Tremblay, G., Cusan, L., Veilleux, R. (1999) EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium. J. Steroid Biochem. Mol. Biol., 69: 51-84. All publications 1999
973. Labrie, F.; (1999). EM-652: a pure anti-estrogen discovered and developed in Canada. The best hope for breast cancer prevention and treatment. Can. Breast Cancer Network, 4: Vol. 4, p. 7. All publications 1999
972. Pelletier, G., Luu-The, V., Charbonneau, A., Labrie, F. (1999) Cellular localization of estrogen receptor beta messenger ribonucleic acid in cynomolgus monkey reproductive organs. Biol. Reprod., 61: 1249-1255. All publications 1999
971. Tremblay, G.B., Tremblay, A., Labrie, F., Giguère, V. (1999) Dominant activity of activation function-1 (AF-1) and differential stoichiometric requirements for AF-1 and -2 in the estrogen receptor α⁄β heterodimeric complex. Mol. Cell. Biol., 19: 1919-1927. All publications 1999
970. Labrie, F. (1999) Potential of DHEA as hormone replacement therapy, in Reproductive Medicine: Past Present and Future. Proceeding of the 10th World Congress on Human Reproduction, Salvador, Bahia, Brazil, Parthenon Publishing, pp 224-237. All publications 1999
969. Labrie, F., Bélanger, A., Luu-The, V., Labrie, C., Simard, J., Lin, S.-X. (1999) DHEA, the precursor of androgens and estrogens in peripheral tissues in the human: intracrinology, in: Kalimi, M. et Regelson, W., eds: Dehydroepiandrosterone (DHEA) Biochemical, Physiological and Clinical Aspects, Berlin, New York, Walter de Gruyter, pp 299-342. All publications 1999
968. Labrie, F., Bélanger, A., Luu-The, V., Simard, J., Lin, S.-X., Cusan, L., Labrie, C. (1999) Role of DHEA transformation into androgens and estrogens in peripheral intracrine tissues, in: Thijssen, J.H.H. et Nieuwenhuyse, H., eds: DHEA a comprehensive review (Proceedings Workshop, Amsterdam 1997), New York, Parthenon Publishing, pp 69-103. All publications 1999
967. Tchernof, A., Labrie, F., Després, J.P. (1999) DHEA, obesity and cardiovascular disease, in: Kalimi, M. et Regelson, W., eds: Dehydroepiandrosterone (DHEA) Biochemical, Physiological and Clinical Aspects, Berlin, Walter de Gruyter, pp 191-213. All publications 1999
966. El-Alfy, M., Luu-The, V., Huang, X.F., Berger, L., Labrie, F., Pelletier, G. (1999) Localization of type 5 17β-hydroxysteroid dehydrogenase, 3 β-hydroxysteroid dehydrogenase and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. Endocrinology, 140: 1481-1491. All publications 1999
965. Labrie, F. (1999) Internal symposium: Editorial. Xth International Congress on Hormonal Steroids (Quebec City, Canada 17-21 June 1998). J. Steroid Biochem. Mol. Biol., 69: 1. All publications 1999
964. Labrie, F., Simard, J., Pasqualini, J.R. (1999) Potential of DHEA as hormonal replacement therapy, 486 pages. All publications 1999
963. Tremblay, A., Tremblay, G.B., Labrie, F., Giguère, V. (1999) Ligand-independent recruitment of SRC-1 to estrogen receptor Beta through phosphorylation of activation function AF-1. Mol. Cell., 3: 513-519. All publications 1999
962. Tremblay, M.R., Luu-The, V., Leblanc, G., Noël, P., Breton, E., Labrie, F., Poirier, D. (1999) Spironolactone-related inhibitors of type II 17Beta-hydroxysteroid dehydrogenase: Chemical synthesis, receptor binding affinities, and proliferative/antiproliferative activities. Bioorg. Med. Chem., 7: 1013-1023. All publications 1999
961. Zhu, D.-W., Campbell, R., Labrie, F., Lin, S.-X. (1999) Crystallization and preliminary crystal structure of the complex of 17Beta-hydroxysteroid dehydrogenase with a dual-site inhibitor. J. Steroid Biochem. Mol. Biol., 70: 229-235. All publications 1999
960. Labrie, F. (1999) International Symposium: Journal of Steroid Biochemistry and Molecular Biology Monaco, 25-28 May 1997. Trends Endocrinol. Metab., 10: 1-5. All publications 1999
959. Ciobanu, L.C., Boivin, R.P., Luu-The, V., Labrie, F., Poirier, D. (1999) Potent inhibition of steroid sulfatase activity by 3-Ο-sulfamate-17α-benzyl (or 4'-tert-butylbenzyl)-estra-1,3,5(10)-trienes: combination of two substituents at positions C3 and C17α of estradiol. J. Med. Chem., 42: 2280-2286. All publications 1999
958. Pelletier, G., Luu-The, V., Tetu, B., Labrie, F. (1999) Immunocytochemical localization of type 5 17beta-hydroxysteroid dehydrogenase in human reproductive tissues. J. Histochem Cytochem., 47: 731-738. All publications 1999
957. Chen, C., Li, X., Singh, S.M., Labrie, F. (1998) Activity of 17beta-(N-alkyl/arylformamido)- and 17beta-[(N-alkyl/aryl) alkyl/arylamido]-4-methyl-4-aza-5alpha-androstan-3-ones as 5alpha-reductase inhibitors in the hamster flank organ and ear. J. Invest. Dermatol., 111: 273-278. All publications 1998
956. Eeles, R.A., Durocher, F., Edwards, S., Teare, D., Badzioch, M., Hamoudi, R., Gill, S., Biggs, P., Dearnaley, D., Ardern-Jones, A., Dowe, A., Shearer, R., McLennan, D.L., Norman, R.L., Ghadirian, P., Aprikian, A., Ford, D., Amos, C., King, T.M., The Cancer Research Campaign/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators, Labrie, F., Simard, J., Narod, S.A., Easton, D., Foulkes, W.D. (1998) Linkage analysis of chromosome 1q markers in 136 prostate cancer families. Am. J. Hum. Genet, 62: 653-658. All publications 1998
955. Labrie, F. (1998) Combined androgen blockade and treatment of localized prostate cancer: a real hope when approaching the year 2000. Endocrine-Related Cancer, 5: 341-351. All publications 1998
954. Labrie, F. (1998) Optimizing combined androgen blockade in prostate cancer, in: Belldegrun, A., Kirby, R.S. et Oliver, R.T.D., eds: New Perspectives in Prostate Cancer, England, ISIS Medical Media, pp 293-311. All publications 1998
953. Labrie, F., Bélanger, A., Luu-The, V., Labrie, C., Simard, J., Cusan, L., Gomez, J.L., Candas, B. (1998) DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging. Steroids, 63: 322-328. All publications 1998
952. Pelletier, G., Luu-The, V., Huang, X.F., Lapointe, H., Labrie, F. (1998) Localization by in situ hybridization of steroid 5alpha-reductase isozyme gene expression in the human prostate and preputial skin. J. Urol., 160: 577-582. All publications 1998
951. Têtu, B., Van der kwast, T., Fradet, Y., Candas, B., Gomez, J.L., Cusan, L., Labrie, F. (1998) Morphologic effects of neoadjuvant hormone therapy on prostate cancer. Mol. Urol., 2: 103-107. All publications 1998
950. van der Kwast, T., Têtu, B., Suburu, E.R., Gomez, J., Lemay, M., Labrie, F. (1998) Cycling activity of benign prostatic epithelial cells during long-term androgen blockade: evidence for self-renewal of luminal cells. J. Pathol., 186: 406-409. All publications 1998
949. Couillard, S., Gutman, M., Labrie, C., Bélanger, A., Candas, B., Labrie, F. (1998) Comparison of the effects of the antiestrogens EM-800 and Tamoxifen on the growth of human breast ZR-75-1 cancer xenografts in nude mice. Cancer Res., 58: 60-64. All publications 1998
948. Couillard, S., Labrie, C., Bélanger, A., Candas, B., Pouliot, F., Labrie, F. (1998) Effect of dehydroepiandrosterone and the antiestrogen EM-800 on growth of human ZR-75-1 breast cancer xenografts. J. Natl. Cancer Inst., 90: 772-778. All publications 1998
947. Luo, S., Labrie, C., Bélanger, A., Candas, B., Labrie, F. (1998) Prevention of development of dimenthylbenz(a)anthracene (DMBA)-induced mammary tumors in the rat by the new nonsteroidal antiestrogen EM-800 (SCH 57050). Breast Cancer Res. Treat., 49: 1-11. All publications 1998
946. Luo, S., Sourla, A., Labrie, C., Gauthier, S., Mérand, Y., Bélanger, A., Labrie, F. (1998) Effect of twenty-four-week treatment with the antiestrogen EM-800 on estrogen-sensitive parameters in intact and ovariectomized mice. Endocrinology, 139: 2645-2656. All publications 1998
945. Martel, C., Labrie, C., Bélanger, A., Gauthier, S., Mérand, Y., Li, X., Provencher, L., Candas, B., Labrie, F. (1998) Comparison of the effects of the new orally active antiestrogen EM-800 with ICI 182 780 and toremifene on estrogen-sensitive parameters in the ovariectomized mouse. Endocrinology, 139: 2486-2492. All publications 1998
944. Martel, C., Provencher, L., Li, X., St-Pierre, A., Leblanc, G., Gauthier, S., Mérand, Y., Labrie, F. (1998) Binding characteristics of novel nonsteroidal antiestrogens to the rat uterine estrogen receptors. J. Steroid Biochem. Mol. Biol., 64: 199-205. All publications 1998
943. Martel, C., Sourla, A., Pelletier, G., Labrie, C., Fournier, M., Picard, S., Li, S., Stojanovic, M., Labrie, F. (1998) Predominant androgenic component in the stimulatory effect of dehydroepiandrosterone on bone mineral density in the rat. J. Endocrinol., 157: 433-442. All publications 1998
942. Sourla, A., Martel, C., Labrie, C., Labrie, F. (1998) Almost exclusive androgenic action of dehydroepiandrosterone in the rat mammary gland. Endocrinology, 139: 753-764. All publications 1998
941. Tremblay, A., Tremblay, G.B., Labrie, C., Labrie, F., Giguère, V. (1998) EM-800, a novel antiestrogen, acts as a pure antagonist of the transcriptional functions of estrogen receptors α and β. Endocrinology, 139: 111-118. All publications 1998
940. Tremblay, G.B., Tremblay, A., Labrie, F., Giguère, V. (1998) Ligand-independent activation of the estrogen receptors α and β by mutations of a conserved tyrosine can be abolished by antiestrogens. Cancer Res., 58: 877-881. All publications 1998
939. Turgeon, C., Gingras, S., Carrière, M.C., Blais, Y., Labrie, F., Simard, J. (1998) Regulation of sex steroid formation by interleukin-4 and interleukin-6 in breast cancer cells. J. Steroid Biochem. Mol. Biol., 65: 151-162. All publications 1998
938. Labrie, F. (1998) DHEA as physiological replacement therapy at menopause. J. Endocrinol. Invest., 21: 399-401. All publications 1998
937. Sourla, A., Flamand, M., Bélanger, A., Labrie, F. (1998) Effect of dehydroepiandrosterone on vaginal and uterine histomorphology in the rat. J. Steroid Biochem. Mol. Biol., 66: 137-149. All publications 1998
936. Coquet, A., Boudreau, N., Merand, Y., Labrie, F. (1998) Validated high-performance liquid chromatographic methods for quantitation of a novel nonsteroidal antiestrogen. J. Chromatogr. A, 828: 247-258. All publications 1998
935. Couture, P., Vohl, M.C., Gagné, C., Gaudet, D., Torres, A.L., Lupien, P.J., Després, J.P., Labrie, F., Simard, J., Moorjani, S. (1998) Identification of three mutations in the low-density lipoprotein receptor gene causing familial hypercholesterolemia among French Canadians. Hum. Mutat. Suppl 1: S226-S231. All publications 1998
<< previous | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 next >>

Biography  |  Publications  |  Scientific Conferences  |  Selected Slide Presentations  |  Awards